The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

Ribonexus, Pierre Fabre sign licensing agreement on small molecules targeting eIF4A

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Ribonexus (previously Aglaia Therapeutics) and French pharmaceutical group Pierre Fabre signed an exclusive license agreement on a series of Pierre Fabre-patented small molecules targeting the eukaryotic translation initiation factor 4A (eIF4A). This target is highly expressed in a variety of solid and hematologic cancers, including melanoma, and associated with resistance to many current therapies.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Roger Lo awarded $2M NIH grant to study melanoma treatment resistance

Roger Lo, professor of medicine, dermatology, and molecular and medical pharmacology and investigator at the UCLA Health Jonsson Comprehensive Cancer Center, was awarded a $2 million grant from NIH to investigate innovative strategies to prevent drug resistance in melanoma treatment and improve the effectiveness of MAPK inhibitors, a common treatment for patients with melanomas that carry the BRAFV600 mutation.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account